儿科

订阅

MedSci主页 / 所有栏目 / 儿科

Biogen公司8亿美元收购Nightstar，以获取其眼科疾病的基因疗法管线

2019-06-07 不详 MedSci原创

BiogenNightstar眼科疾病腺相关病毒基因疗法
关注

Biogen宣布已完成收购Sycona的Nightstar Therapeutics，这是一家临床阶段基因治疗公司，专注于使用腺相关病毒（AAV）基因疗法治疗遗传性视网膜疾病。

Biogen宣布已完成收购Sycona的Nightstar Therapeutics，这是一家临床阶段基因治疗公司，专注于使用腺相关病毒（AAV）基因疗法治疗遗传性视网膜疾病。

Biogen今年3月宣布以每股25.50美元现金，总价为8亿美元收购Nightstar。通过此次收购，Biogen现已在眼科疾病领域增加了两个中期至晚期临床以及临床前基因治疗项目。

Nighstar的主要候选药是NSR-REP1，用于治疗choroideremia（CHM），这是一种罕见的退行性X连锁遗传性视网膜疾病，可引起患者失明并且目前还没有获批的药物。

首席执行官Michel Vounatsos表示，此次收购标志着"Biogen的重大成就"。

他继续说道，"对Nightstar的收购进一步巩固了我们的研发管道，我们期待着为患者提供突破性疗法，以减缓或阻止一系列遗传性视网膜疾病所引起的失明。"

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1918727, encodeId=8db51918e27ac, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jul 28 19:45:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800701, encodeId=29ad1800e01f1, content=<a href='/topic/show?id=ba15e28714e' target=_blank style='color:#2F92EE;'>#眼科疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72871, encryptionId=ba15e28714e, topicName=眼科疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Thu Apr 09 17:45:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404336, encodeId=893c14043361e, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Sun Jun 09 11:45:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605345, encodeId=ae1c160534538, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Sun Jun 09 11:45:00 CST 2019, time=2019-06-09, status=1, ipAttribution=)]
    2019-07-28 sunylz

    #Bio#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1918727, encodeId=8db51918e27ac, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jul 28 19:45:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800701, encodeId=29ad1800e01f1, content=<a href='/topic/show?id=ba15e28714e' target=_blank style='color:#2F92EE;'>#眼科疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72871, encryptionId=ba15e28714e, topicName=眼科疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Thu Apr 09 17:45:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404336, encodeId=893c14043361e, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Sun Jun 09 11:45:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605345, encodeId=ae1c160534538, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Sun Jun 09 11:45:00 CST 2019, time=2019-06-09, status=1, ipAttribution=)]
    2020-04-09 ligang4439

    #眼科疾病#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1918727, encodeId=8db51918e27ac, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jul 28 19:45:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800701, encodeId=29ad1800e01f1, content=<a href='/topic/show?id=ba15e28714e' target=_blank style='color:#2F92EE;'>#眼科疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72871, encryptionId=ba15e28714e, topicName=眼科疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Thu Apr 09 17:45:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404336, encodeId=893c14043361e, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Sun Jun 09 11:45:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605345, encodeId=ae1c160534538, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Sun Jun 09 11:45:00 CST 2019, time=2019-06-09, status=1, ipAttribution=)]
    2019-06-09 qjddjq

    #Biogen#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1918727, encodeId=8db51918e27ac, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jul 28 19:45:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800701, encodeId=29ad1800e01f1, content=<a href='/topic/show?id=ba15e28714e' target=_blank style='color:#2F92EE;'>#眼科疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72871, encryptionId=ba15e28714e, topicName=眼科疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=869698, createdName=ligang4439, createdTime=Thu Apr 09 17:45:00 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404336, encodeId=893c14043361e, content=<a href='/topic/show?id=a4f13430af' target=_blank style='color:#2F92EE;'>#Biogen#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3430, encryptionId=a4f13430af, topicName=Biogen)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0dab2457651, createdName=qjddjq, createdTime=Sun Jun 09 11:45:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605345, encodeId=ae1c160534538, content=<a href='/topic/show?id=b94d1e90023' target=_blank style='color:#2F92EE;'>#TST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17900, encryptionId=b94d1e90023, topicName=TST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30e219383639, createdName=ms3153534357578991, createdTime=Sun Jun 09 11:45:00 CST 2019, time=2019-06-09, status=1, ipAttribution=)]
    2019-06-09 ms3153534357578991

    #TST#

    0